The present invention relates to a pharmaceutical composition, comprising

(a) a phosphodiesterase 5 inhibitor or a pharmaceutically acceptable salt thereof and

(b) at least one of the active ingredients selected from the group consisting of

• (i) an anti-diabetic agent;
• (ii) HMG-Co-A reductase inhibitors;
• (iii) an anti-hypertensive agent; and
• (iv) a serotonin reuptake inhibitor (SSRI)

  or, in each case, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The pharmaceutical composition may be employed for the treatment of sexual dysfunction, hyperglycemia, hyperinsulinaemia, hyperlipidaemia, hypertriglyceridemia, diabetes, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X, erectile dysfunction, coronary heart disease, hypertension, especially ISH, angina pectoris, myocardial infarction, stroke, vascular restenosis, endothelial dysfunction, impaired vascular compliance, congestive heart failure.